Long Term Psychiatric and Endocrine Complications Following Hematopoietic Stem Cell Transplantation in Hematologic Disease in Korea: A Nation-wide Cohort Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Numerous patients experience long-term complications after hematopoietic stem cell transplantation (HSCT). This study aimed to identify the frequency and risk factors for psychiatric and endocrine complications following HSCT through big data analyses. Materials and Methods We established a cohort of patients with hematologic disease who underwent HSCT in Korea between 2010 and 2012 using the Health Insurance Review & Assessment Service data. A total of 3,636 patients were identified, and insurance claims were tracked using psychiatric and endocrine diagnostic International Classification of Diseases, 10th Revision codes for the ensuing decade. We identified the incidence rates of long-term complications based on the baseline disease and HSCT type. Prognostic factors for each complication were scrutinized using logistic regression analysis. Results A total of 1,879 patients underwent allogeneic HSCT and 1,757 patients received autologous HSCT. Post-HSCT, 506 patients were diagnosed with depression, 465 with anxiety disorders, and 659 with diabetes. The highest incidence of long-term complications occurred within the first year post-HSCT (12.2%), subsequently decreasing over time. Risk factors for depressive disorders after allogeneic HSCT included female sex, a total body irradiation–based conditioning regimen, and cyclosporine. Identified risk factors for diabetes mellitus comprised old age, total body irradiation–based conditioning regimen, and non-antithymocyte globulin protocol. Regarding autologous HSCT, only female sex was identified as a risk factor for depressive disorders, whereas elderly patients and those with multiple myeloma were identified as poor prognostic factors for diabetes mellitus. Conclusion The incidence of long-term psychiatric and endocrine complications post-HSCT remains high, and patients with risk factors for these complications require vigilant follow-up.
Abstract
Purpose Numerous patients experience long-term complications after hematopoietic stem cell transplantation (HSCT). This study aimed to identify the frequency and risk factors for psychiatric and endocrine complications following HSCT through big data analyses. Materials and Methods We established a cohort of patients with hematologic disease who underwent HSCT in Korea between 2010 and 2012 using the Health Insurance Review & Assessment Service data. A total of 3,636 patients were identified, and insurance claims were tracked using psychiatric and endocrine diagnostic International Classification of Diseases, 10th Revision codes for the ensuing decade. We identified the incidence rates of long-term complications based on the baseline disease and HSCT type. Prognostic factors for each complication were scrutinized using logistic regression analysis. Results A total of 1,879 patients underwent allogeneic HSCT and 1,757 patients received autologous HSCT. Post-HSCT, 506 patients were diagnosed with depression, 465 with anxiety disorders, and 659 with diabetes. The highest incidence of long-term complications occurred within the first year post-HSCT (12.2%), subsequently decreasing over time. Risk factors for depressive disorders after allogeneic HSCT included female sex, a total body irradiation–based conditioning regimen, and cyclosporine. Identified risk factors for diabetes mellitus comprised old age, total body irradiation–based conditioning regimen, and non-antithymocyte globulin protocol. Regarding autologous HSCT, only female sex was identified as a risk factor for depressive disorders, whereas elderly patients and those with multiple myeloma were identified as poor prognostic factors for diabetes mellitus. Conclusion The incidence of long-term psychiatric and endocrine complications post-HSCT remains high, and patients with risk factors for these complications require vigilant follow-up.
참고문헌 (30)
- Majhail NS, "Indications for autologous and allogeneic hematopoietic cell transplantation : guidelines fromthe American Society for Blood and Marrow Transplantation", Biol Blood Marrow Transplant, 21, pp.1863~1869 (2015)
- Passweg JR, "Hematopoietic cell transplantation and cellular therapy survey of the EBMT : monitoring of activities and trends over 30 years", Bone Marrow Transplant, 56, pp.1651~1664 (2021)
- D’Souza A, "Current use of and trends in hematopoietic cell transplantation in the United States", Biol Blood Marrow Transplant, 26, pp.e177~e182 (2020)
- Iida M, "Advances in hematopoietic stem cell transplantation in the Asia-Pacific region : the second report from APBMT 2005-2015", Bone Marrow Transplant, 54, pp.1973~1986 (2019)
- Maurer K, "Posttransplant cyclophosphamide vs tacrolimus-basedGVHD prophylaxis : lower incidence of relapse and chronicGVHD", Blood Adv, 7, pp.3903~3915 (2023)
- Niederwieser D, "One and a half million hematopoieticstem cell transplants : continuous and differential improvement in worldwide access with the use of non-identical family donors", Haematologica, 107, pp.1045~1053 (2022)
- Gagelmann N, "Dose intensity for conditioning inallogeneic hematopoietic cell transplantation : can we recommend"when and for whom"in 2021?", Haematologica, 106, pp.1794~1804 (2021)
- Muffly L, "Increasing use of allogeneic hematopoieticcell transplantation in patients aged 70 years and older in theUnited States", Blood, 130, pp.1156~1164 (2017)
- Passweg JR, "Use of haploidentical stem cell transplantation continues to increase : the 2015 European Society forBlood and Marrow Transplant activity survey report", BoneMarrow Transplant, 52, pp.811~817 (2017)
- Wauben B, "Assessing long-term effectsafter stem cell transplantation : design of the MOSA study", JClin Epidemiol, 148, pp.10~16 (2022)
- Gratwohl A, "Cause of death after allogeneic haematopoietic stem cell transplantation(HSCT)in early leukaemias : anEBMT analysis of lethal infectious complications and changes over calendar time", Bone Marrow Transplant, 36, pp.757~769 (2005)
- Majhail NS, "Long-term complications after hematopoietic cell transplantation", Hematol Oncol Stem Cell Ther, 10, pp.220~227 (2017)
- Wingard JR, "Long-term survival and late deaths after allogeneic hematopoietic cell transplantation", J Clin Oncol, 29, pp.2230~2239 (2011)
- Martin PJ, "Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation", J Clin Oncol, 28, pp.1011~1016 (2010)
- Kim GE, "Increased prevalence of depression in South Korea from 2002 to 2013", Sci Rep, 10, pp.16979~ (2020)
- Hjermstad MJ, "The course of anxiety and depression during the first year after allogeneic or autologous stem cell transplantation", Bone Marrow Transplant, 24, pp.1219~1228 (1999)
- Cheon J, "Late complications and quality of life assessment for survivors receiving allogeneic hematopoietic stem cell transplantation", Support Care Cancer, 29, pp.975~986 (2021)
- Rueda-Lara M, "Psychiatric and psychosocial challenges in patients undergoing haematopoietic stem cell transplants", Int Rev Psychiatry, 26, pp.74~86 (2014)
- Sun CL, "Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation : a report from the Bone Marrow Transplant Survivor Study(BMTSS)", Blood, 118, pp.4723~4731 (2011)
- Nakamura ZM, "Psychiatric care in hematopoietic stem cell transplantation", Psychosomatics, 60, pp.227~237 (2019)
- Hirabayashi K, "Risk factors for diabetes mellitus and impaired glucose tolerance following allogeneic hematopoietic stem cell transplantation in pediatric patients with hematological malignancies", Int J Hematol, 99, pp.477~486 (2014)
- Atilla E, "A review of late complications of allogeneic hematopoietic stem cell transplantations", Clin Transplant, 31, pp.e13062~ (2017)
- Chemaitilly W, "Endocrine complications of hematopoietic stem cell transplantation", Endocrinol Metab Clin North Am, 36, pp.983~998 (2007)
- Griffith ML, "Diabetes mellitus after hematopoietic stem cell transplantation", Endocr Pract, 16, pp.699~706 (2010)
- Baker KS, "Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation : a report from the bone marrow transplantation survivor study", Blood, 109, pp.1765~1772 (2007)
- Neville KA, "Hyperinsulinemia, impaired glucose tolerance, and diabetes mellitus in survivors of childhood cancer : prevalence and risk factors", J Clin Endocrinol Metab, 91, pp.4401~4407 (2006)
- Bonanomi S, "Distinctive characteristics of diabetes mellitus after hematopoietic cell transplantation during childhood", Pediatr Transplant, 10, pp.461~465 (2006)
- Subramanian S, "Immunosuppressive agents : effects on glucose and lipid metabolism", Endocrinol Metab Clin North Am, 36, pp.891~905 (2007)
- Penfornis A, "Immunosuppressive drug-induced diabetes", Diabetes Metab, 32, pp.539~546 (2006)
- Ravindran VK, "Insulin hyposecretion in nondiabetic, tacrolimus-treated renal transplant recipients more than 6 months posttransplantation", Transplantation, 87, pp.1870~1876 (2009)